Mosliciguat Phase 2 Data Shows 52.7m Walk Improvement, Analysts Hike Targets
ROIV has more than doubled off its 52-week low of $13.81.
Summary
Roivant's inhaled mosliciguat delivered strong Phase 2 PHocus results in PH-ILD: a -56.3% placebo-adjusted PVR reduction and a 52.7-meter improvement in 6-minute walk distance at 24 weeks, with no major safety signals. This follows the FDA approval of Lisraya in late August and adds another late-stage asset with blockbuster potential. TD Cowen raised its target to $55 from $50 and HC Wainwright to $47 from $41, both maintaining Buy ratings. The stock is trading near its 52-week high of $42.50, reflecting growing confidence in the pipeline. Next catalyst: Phase 3 initiation for mosliciguat, expected to be announced in the coming months.
At the time of this announcement, ROIV was trading at $40.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.5B. The 52-week trading range was $13.81 to $42.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.